US Edition
Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio – Optimum Strategic CommunicationsLink to: Weekly roundup: Wins in and out of the clinicScroll to top
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio – Optimum Strategic CommunicationsLink to: Weekly roundup: Wins in and out of the clinicScroll to top
Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech developing an oral therapy for frontotemporal dementia, today announces the appointment of Jacob Falck Hansen as Chief Executive Officer (CEO). Jacob Falck Hansen brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
